October 18, 2017 Source: Yicaiglobal 415
Medical equipment maker MagicMed Technologies (Beijing) Co. has secured USD1.5 million (CNY10 million) in pre-series A financing. The funds will help the firm hasten the commercialization of its Magitor Cell, a single channel electrocardiographic monitoring device.
Focusing on electrocardiographic monitoring, MagicMed acquires physiological information with professional medical gear, enabling it to analyze big data and conduct smart diagnoses. The China Food and Drug Administration has certified the Magitor Cell, 36kr.com quoted MagicMed founder Ma Long as saying today.
Magitor Cell is mainly used to help detect arrhythmias. Users attach an electrode patch to themselves to screen electrical cardiac signals and record an electrocardiogram. It is easy to use and patients can operate it at homes.
MagicMed will work with health facilities and community medical centers in towns and villages to cover end users. It will team up with third-party health service platforms to provide them with data monitoring and analysis services and help hospitals follow patients’ post-operation and post-discharge rehabilitation conditions.
By Dduyour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.